The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | IPSS-R vs IPSS-M for MDS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, outlines the caveats of the Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes (MDS), and comments on the potential impact of the new molecular IPSS (IPSS-M) in treatment decisions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Incyte: Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Agios: Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy.
